Our Team

At Nemean, Tom has worked alongside a number of ASX-Listed medical device, biotechnology and technology companies in both an investor relations (IR) capacity and corporate development. He has provided advisory services to a number of private companies in relation to capital structuring and initial public offerings. In his corporate development consulting role, Tom assisted Ellex Medical lasers (ASX:ELX, now ASX:EYE) on the sale of the Lasers & Ultrasound business for A$100 million in cash to Lumibird Group SA in 2020, representing 1.9x revenues and 10.6x EBITDA and the subsequent return of capital/dividend from sale proceeds to shareholders.  In June 2023, an IR client, Limeade (ASX:LME) announced a $111 million all-cash takeover by WebMD Health Services, representing a 325% premium to the last price. The transaction is expected to close in August 2023.

Prior to establishing Nemean, Tom was the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (ASX:SRX) and a member of the Senior Leadership Team.  Sirtex is a global medical device player focused on the sale and development of innovative interventional oncology products and was an S&P/ASX 200 Company (also a Top 100 Company from 2015-2017) prior to it being sold.  

In January 2018, it was announced that Sirtex was to be acquired by Varian Medical Systems (NYSE:VAR) for A$1.6 billion.  In May 2018, a consortium led by CDH Investments, a China-based alternative asset manager with over US$20 billion under management, announced a superior takeover proposal for Sirtex, valuing the company at A$1.9 billion. The transaction was successfully completed in September 2018. This corporate deal represented the largest ever medical device transaction in Australia by value and was a Top Ten Med Tech M&A deal globally over the previous 12 months.   The exit price of $33.60 per share represented a ten year average annual return of over 27% for investors.

Tom was instrumental in developing corporate strategies designed to maximise shareholder value.  This included expansion of the share register targeting US and European institutional investors, several group-wide restructuring plans, initiating and execution of share buy-backs, an active non-core asset divestment program and the assessment of M&A and other partnering opportunities to drive value.

Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies. Tom developed this sector capability to become a major leader in terms of deal flow and returns. During this time, approximately $200 million in equity capital was raised for selected portfolio companies. Tom has previously advised leading ASX Healthcare & Biotechnology companies including Sirtex Medical (ASX:SRX), Biota Holdings Limited (ASX:BTA), Ellex Medical Lasers (ASX:ELX), CogState (ASX:CGS) and AtCor Medical Holdings (ASX:ACG).  Tom also held an RG146 certification to provide financial advice to retail clients during this period.

Tom holds a PhD (with commendation) from the University of Adelaide and an MBA from Deakin University. He is a Member of the Australian Institute of Company Directors (MAICD) and the Australasian Investor Relations Association (AIRA).

Tom is currently the Non-Executive Chairman of Arovella Therapeutics (ASX:ALA), a Director of  Invex Therapeutics Limited (ASX:IXC), Neurotech International (ASX:NTI) and Chairman/Co-Founder of Signature Oncology Pty Ltd.